Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.30 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323276 | 0.91 | ALDH1A1 (0.30) | L3MBTL1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL26327371 | 0.69 | SLC2A1 (0.31) | L3MBTL1ALDH1A1MAPTSLC2A1EHMT2 | |
| SCHEMBL25495279 | 0.66 | KDR (0.50) | PARP1KDR | |
| SCHEMBL26323497 | 0.65 | MAPT (0.50) | MAPTMAPK1PARP1 | |
| SCHEMBL26323330 | 0.62 | KDR (0.42) | ALDH1A1MAPTMAPK1TDP1HTT | |
| SCHEMBL23999675 | 0.61 | KDR (0.53) | PARP1KDR | |
| SCHEMBL30180450 | 0.61 | KDR (0.53) | PARP1KDR | |
| SCHEMBL25484070 | 0.60 | SLC2A1 (0.33) | L3MBTL1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL23999830 | 0.60 | KDR (0.44) | KDR | |
| SCHEMBL31125046 | 0.60 | KDR (0.56) | MAPTLMNAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | L3MBTL1 2295/4885ALDH1A1 4544/4885GAA 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.